The following criteria is provided for health care professionals.

Inclusion criteria:

• Patients must have a known diagnosis of multiple myeloma with evidence of measurable disease, as defined below:
  • Serum M-protein ≥ 1 g/dL (≥ 0.5 g/dL in case of immunoglobulin A [IgA] disease), AND/OR
  • Urine M-protein ≥ 200 mg/24 hours, OR
  • In the absence of measurable M-protein, serum immunoglobulin free light chain ≥ 10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio (< 0.26 or > 1.65).
• Patients must have received prior treatment with an immunomodulatory drug (IMiD) (for ≥ 2 cycles or ≥ 2 months of treatment) and a proteasome inhibitor (PI) (for ≥ 2 cycles or ≥ 2 months of treatment).
• Patients must have received at least 3 prior lines of therapy (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).
• Patient must have achieved MR or better with any anti-myeloma therapy (ie, primary refractory disease is not eligible).

Exclusion criteria:

• Prior exposure to isatuximab or participated clinical studies with isatuximab.
• Prior exposure to any agent (approved or investigational) that blocks the programmed cell death-1 (PD-1)/PD-L1 pathway.
• Evidence of other immune related disease/conditions.
• History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
• Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
• Has allogenic haemopoietic stem cell (HSC) transplant.
• Prior treatment with idelalisib (a PI3K inhibitor).
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2.
• Poor bone marrow reserve.
• Poor organ function.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.